The other study was performed by our own group in a multicentre setting [10], in which strong PSMA expression in tumour microvessels was found but without a correlation with uptake intensity on PSMA PET, most likely explained by tumour heterogeneity and sampling errors and/or differences between the PSMA-radioligands used (between centres). The gene discussed is FOLH1; the disease is neoplasm.